Le Lézard
Classified in: Health, Science and technology
Subject: FDA

Hycor Biomedical Receives FDA 510(k) Clearance for NOVEOStm, Its Modern Allergy Testing Instrument


GARDEN GROVE, Calif., Dec. 19, 2018 /PRNewswire/ -- Hycor Biomedical, a leading manufacturer of in vitro diagnostic products for allergy and autoimmune testing, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its new allergy testing system, NOVEOS.

NOVEOS

"Hycor has a long history of being at the forefront of allergy diagnostic testing and we developed NOVEOS to be a paradigm-changing diagnostic system for laboratorians with limited options in the allergy space," said Dr. Fei Li, President and Chief Executive Officer at Hycor. "The clearance of NOVEOS underscores our commitment to driving allergy immunodiagnostics into the 21st century for patients, laboratories and physicians."

Employing microparticles, chemiluminescence and liquid ready-to-use reagent, NOVEOS provides the first-of-its-kind technology to be introduced for routine allergy testing labs in over 20 years. The system was designed to address common issues laboratorians face with current technologies by offering several innovative features, including a significant reduction in sample size, reduced blood-based interferences, less variability within allergen lots, increased accuracy and improved walk-away time for laboratory technicians.

The company also received simultaneous clearance for the system's first Specific IgE (sIgE) assay to detect Dust Mite allergen (D001), and is focused on the development of additional assays to provide a comprehensive menu to customers.

"This new microbead-based IgE antibody assay technology looks promising as a novel diagnostic testing option with a unique small sample size requirement for identifying sensitization in patients suspected of having allergic disease," said Robert G. Hamilton, Ph.D., D.ABMLI, Professor of Medicine and Pathology at Johns Hopkins University School of Medicine.

About Hycor Biomedical
Founded in 1981, Hycor is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, Hycor has expanded its presence into allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, Hycor markets the HYTEC® and AUTOSTAT® brands and recently added the NOVEOS product line, which recently received CE mark in the European Union and FDA clearance in the United States. The company is focused on delivering quality products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit www.HYCORbiomedical.com.

 

Hycor Biomedical (PRNewsfoto/Hycor Biomedical)

SOURCE Hycor Biomedical


These press releases may also interest you

at 13:00
The "PEGylated Proteins Market 2023-2028" report has been added to ResearchAndMarkets.com's offering. The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and is projected to reach $15.9 billion by the end of...

at 12:58
Dr. Paul Carey DDS, a distinguished figure in the medical community, is proud to announce the continuation of the Dr. Paul Carey Scholarship for Medical Students, an esteemed scholarship program aimed at supporting aspiring medical professionals in...

at 12:51
Dr. Scott Kamelle, a trailblazer in the realm of robotic surgery, begins his work with the highly anticipated Da Vinci 5 robotic surgery system, marking a monumental advancement in surgical precision, efficiency, and patient care. With an array of...

at 12:51
Angel Care Medical, a provider of durable medical equipment (DME), along with President, Dan Halas, is thrilled to announce integration capabilities with PointClickCare, a leading healthcare technology platform enabling meaningful care collaboration...

at 12:32
The countdown has begun for Northern Colorado's most exhilarating fitness competition of the year as "Health4Heroes" gears up to host its highly anticipated 3rd Annual Military and First Responder-inspired "Guardian Games & Expo" on Saturday, May 18,...

at 12:06
A Philadelphia jury has returned a $725.5 million verdict against ExxonMobil, finding the company's failure to warn about known health risks of exposure to cancer-causing benzene in its petroleum products was responsible for a former service station...



News published on and distributed by: